Second UK vaccine to combat coronavirus to begin human testing – Bloomberg
|According to Bloomberg, London’s Imperial College vaccine to cure the coronavirus infection, is likely to begin its human trials this week.
The tests are backed by 41 million pounds ($52 million) in UK funding along with another 5 million pounds of donations, including contributions from the public, as cited by the government.
Additional details
“The work, led by Imperial’s Robin Shattock, is based on technology called self-amplifying RNA. “
“If the vaccine yields a promising immune response, larger trials would begin later in the year with about 6,000 volunteers. “
“Imperial’s RNA vaccine works by injecting new genetic code into muscle, which it instructs to make a protein found on the surface of the virus, triggering a protective immune response.”
Market reaction
The above vaccine news likely adds to the optimism seen around Wall Street, with S&P 500 futures up 0.10% in early trades, pointing to a positive start on the Japanese markets.
Meanwhile, the US dollar index is consolidating near Monday’s low of 96.60. The cable trades firmer above the 1.26 handle ahead of the UK labor market report.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.